An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis

Clinical trial NCT01142557 · COMPLETED

Trial details

NCT number: NCT01142557
Sponsor: Merck KGaA, Darmstadt, Germany
Status: COMPLETED
Study type: OBSERVATIONAL

Multiple Sclerosis

Start date: 2004-06-01
Primary completion: 2005-11-01
Enrollment: 522

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.